Psilocybin enhances sociability only in altered behavioural state and does not need an awake experience to be effective

Paper. Song C, Chang T, Buchborn T et al.. Nature Communications, 27 Aug 2026.

Tags: Animal, Psilocybin, Depression, Autism.

Weekly Science Digest, 20 Jul 2026 to 2 Oct 2026, finding 7: Do you need the trip for the benefit?

In a mouse model of autism, one dose of psilocybin made the animals lastingly more social, even when it was given under anesthesia. A second mouse study found psilocybin still helped fear extinction when the 5-HT2A receptor, the one behind the trip, was blocked. A commentary in the International Journal of Drug Policy argues that removing the experience removes much of the therapy.

How much weight it carries: Both findings are in mice. Whether the experience matters in humans is still open. (Mice, Preclinical, Peer reviewed)

Weekly Science Digest, 26 Sep 2026 to 2 Oct 2026, finding 1: Can you get the effect without the trip?

A single psilocybin dose raised sociability in autism-model mice even when given under anaesthesia.

In Cntnap2-knockout mice the effect was durable; isogenic controls showed no change. Separately, a phase 1 study in 56 healthy adults mapped psilocybin from 0.5 to 4.0 mg, finding dose-proportional psilocin exposure, placebo-comparable adverse events and somnolence as the main signal — a defined subperceptual range.

Read the original

—
Node—
Statuslive
Throughput—